TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03905564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg combination
Description: Delayed-release tablet containing a fixed-dose combination of doxylamine succinate 10 mg and pyridoxine hydrochloride 10 mg (product of Tecnandina, S.A. TENSA).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclegis (Registered Trademark)
Description: Delayed-release tablet containing a fixed-dose combination of doxylamine succinate 10 mg and pyridoxine hydrochloride 10 mg (product of Duchesnay Inc.).
Study: NCT03123536

Intervention type: DEVICE
Intervention: Point-of-care Ultrasound
Description: Patients' management in the point-of-care ultrasound group will be adjusted according to the results of ultrasound, whereas patients in the control group the decisions about the management were made by the experience of clinical team.
Study: NCT00415194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 mg/m\^2, IV, every 21 days, six 21 day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 75 mg/m\^2, administered IV, every 21 days, six 21 day cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cisplatin
Description: 75 mg/m\^2, administered IV, every 21 days, six 21 day cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Approximately 100 mL normal saline administered IV, every 21 days, six 21 day cycles
Study: NCT01751035

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk Reduction through Family Therapy
Description: RRFT is an integrative, ecologically-based approach to risk reduction and treatment. A Stage 1a feasibility trial and a Stage 1b pilot randomized controlled trial (RCT) evaluating RRFT have been completed. This Stage 1 work has resulted in a treatment manual, a clinician training protocol, and a quality assurance system. Preliminary findings from these studies are promising, indicating that RRFT can be readily learned and implemented with fidelity, and that it can lead to improvements in drug use and drug use-related risk and protective factors, PTSD symptoms, and risky sexual behaviors.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual
Description: Participants assigned to the TAU condition will receive the standard treatment that a CSA victim would typically receive at community advocacy centers. In addition to treatment that is typically offered at the CACs, this will include a referral for substance abuse evaluation and may include referrals to other agencies in the community. TAU has been utilized as a comparison condition for several behavioral treatment evaluations involving adolescent substance abuse.
Study: NCT04361903

Intervention type: DRUG
Intervention: Ruxolitinib Oral Tablet
Description: Ruxolitinib Oral Tablet dosage of at least 20 mg x 2 / day in the first 48 hours
Study: NCT01175811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro Premix
Description: Participant dependent dose, administered subcutaneously for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Participant dependent dose, administered subcutaneously for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Participant dependent dose, administered subcutaneously for 24 weeks
Study: NCT02931006

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: water

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: bovine milk
Study: NCT02400242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACY-241
Description: Dose escalation up to 480 mg administered orally on Days 1-21 of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: 4 mg qd dosed on days 1-21 of a 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg qd on days 1, 8, 15, 22
Study: NCT00775905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amlodipine 10 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amlodipine 10 mg tablet
Study: NCT01780987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: 10 mg BID for 7 days followed by 5 mg BID for 23 weeks (total 24 weeks)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Description: Dosing adjustment based on APTT = 1.5-2.5 times the control value, and until INR ≥ 1.5 for 5 days or more

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Dosing for 24 weeks to target INR range between 1.5-2.5
Study: NCT03589586

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DermACELL AWM
Description: DermACELL AWM is a sterile, ready to use acellular dermal matrix
Study: NCT01529398

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sensorimotor training (SMT)
Description: The group realized 16 weeks of sensorimotor training, twice a week, with duration of 30 minutes each session. The intervention included agility and coordination exercises, perturbation training and stretching exercises. Also, the participants received orientation about the knee osteoarthritis.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance training (RT)
Description: The group realized 16 weeks of resistance training for the quadriceps and hamstring muscles, twice a week, with duration of 30 minutes each session. The intervention included strength leg raises, simple quadriceps and hamstring strengthening with cuff weights realized in 3 sets of ten repetition maximum(10RM) for each muscle group. The group also realized stretching exercises for lower limbs and received orientation about the knee osteoarthritis.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control group (CG)
Description: Patients in this group also received information about knee osteoarthritis and realized the same warm-up and cool-down intervention realized in the interventional groups. During 16 weeks they went to the ambulatory twice a week to perform 5 minutes of stationary bicycle and 5 minutes of stretching exercises for lower limbs.
Study: NCT01155453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212
Study: NCT01324635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Given PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy
Description: Undergo SBRT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-life assessment
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery
Description: Undergo stereotactic radiosurgery
Study: NCT01608386

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IVC clamping
Description: in right hepatectomy,use anterior approach and infrahepatic Inferior Vena Cava clamping.
Study: NCT01008852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBI-087
Description: 200 mg SC Day 1, Placebo Day 15, Placebo Day 84 + Methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBI-087
Description: 200 mg SC Day 1, 200 mg SC Day 15, Placebo Day 84 + Methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBI-087
Description: 200 mg SC Day 1, Placebo Day 15, 200 mg SC Day 84 + Methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBI-087
Description: 200 mg SC Day 1, 200 mg SC Day 15, 200 mg SC Day 84 + Methotrexate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Day 1, Placebo Day 15, Placebo Day 84 + Methotrexate
Study: NCT01247246

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SCV-07
Description: clinical trial material; (placebo or SCV 07) at doses of 0 (placebo), 0.1, 0.3, and 1.0 mg/kg will be administered sc

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SCV-07
Description: clinical trial material; (placebo or SCV 07) at doses of 0 (placebo), 0.1, 0.3, and 1.0 mg/kg will be administered sc

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SCV-07
Description: clinical trial material; (placebo or SCV 07) at doses of 0 (placebo), 0.1, 0.3, and 1.0 mg/kg will be administered sc

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00601809

Intervention type: OTHER
Group type: OTHER
Intervention: traditional conservative treatment (TT)
Description: In the control group (TT: Traditional Treatment), the patients have been treated as in our daily surgical practice of traditional conservative treatment for ASIO, consisting in nil per os diet, nasogastric tube (NGT) decompression and intravenous fluid resuscitation therapy with electrolytes imbalances correction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gastrografin®: G
Description: The study group (GG: Gastrografin Group) received, beyond the traditional conservative treatment for ASIO above mentioned, a G meal with a follow-through study immediately.
Study: NCT04295356

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CT-P17
Description: subjects will receive a single dose (40 mg) of CT-P17 via AI on Day 1 followed by 10 weeks

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CT-P17
Description: subjects will receive a single dose (40 mg) of CT-P17 via PFS on Day 1 followed by 10 weeks
Study: NCT00924729

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 0.5% ophthalmic solution
Description: Administer moxifloxacin study drug prior to cataract surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Besifloxacin 0.6% ophthalmic suspension
Description: Administer besifloxacin study drug prior to cataract surgery.
Study: NCT03179410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: 10 mg/kg intravenously every 2 weeks
Study: NCT03823807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SH-1028
Description: Oral,100mg or 200mg ,QD, fasted
Study: NCT02269384

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Experimental Noxious Stimulus
Description: Localized manual pressure will be placed up predetermined points on the lower extremity until maximum pain tolerance levels are reached.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Experimental Noxious Stimulus
Description: Localized manual pressure will be placed up predetermined points on the lower extremity until maximum pain tolerance levels are reached.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Memory of Experimental Noxious Stimulus
Description: Subjects will be asked to visualize previously experience experimental noxious stimulus
Study: NCT03692780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Careseng 1370
Description: 4,000mg granules in sachet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4,000mg granules in sachet
Study: NCT04680520

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental (Doublebase Gel® or Diprobase Cream®)
Description: Emollient (Doublebase Gel® or Diprobase Cream®) use on the skin. The emollient should be applied at least once a day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best practice skin care advice booklet
Description: This is a booklet containing advice on best practice skin care. This will contain information on avoiding soap etc.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best practice skin care advice booklet
Description: This is a booklet containing advice on best practice skin care. This will contain information on avoiding soap etc.
Study: NCT01522924

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling practice sessions
Description: Dental students will complete the first questionnaire before a tobacco cessation lecture and the second questionnaire after the lecture, counseling practice sessions using standardized patients and a debriefing session.
Study: NCT01700296

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Best care
Description: Best Care: subjects are randomly assigned to the Best care regardless MRC class and severity of symptoms through:~1. 10 weeks of rehabilitation (2 hours, 2 times a week) by Region Zealand's instructions on sundhed.dk. COPD rehabilitation includes physical exercise, smoking cessation, medication, nutrition education and psychosocial support and patient education. Rehabilitation provided by a multidisciplinary effort with lung nurse, dietician and physiotherapist according to national and international guidelines (1.5) (6) (24) (25)~2. Outpatient follow-up every 3 months, a total of 5 visits, and during these visits various subjective, clinical, paraclinical and invasive parameters.
Study: NCT02269384

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Memory of Experimental Noxious Stimulus
Description: Subjects will be asked to visualize previously experience experimental noxious stimulus
Study: NCT03425877

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dual Task
Description: This section includes three tasks of different types (upper limb motor, lower limb motor, cognitive) that will be performed with a greater cognitive load. Elbow N-back (Dual Task Motor upper limbs): The subject is required to reconfigure the arrangement of the floppy disks on a different blade, by moving only one disk at a time and by putting a disk on another bigger disk, never on a smaller one. Walking + Nback (Dual Task Motor lower limbs): The subject is required to walk while subtracting from 100 to 3 in 3. Problem Solving (Dual Task Cognitive): The subject is subjected to a deductive logic puzzle.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dual Task
Description: This section includes three tasks of different types (upper limb motor, lower limb motor, cognitive) that will be performed with a greater cognitive load. Elbow N-back (Dual Task Motor upper limbs): The subject is required to reconfigure the arrangement of the floppy disks on a different blade, by moving only one disk at a time and by putting a disk on another bigger disk, never on a smaller one. Walking + Nback (Dual Task Motor lower limbs): The subject is required to walk while subtracting from 100 to 3 in 3. Problem Solving (Dual Task Cognitive): The subject is subjected to a deductive logic puzzle.
Study: NCT03306368

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Youth Opioid Recovery Support
Description: The components of the Youth Opioid Recovery Support intervention are:~XR-NTX, home delivery of XR-NTX, the family framework approach engages and empowers families, assertive continuing care incorporates outreach, home delivery of XR-NTX, contingency management.
Study: NCT00959361

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pharmaceutical care
Description: consultation with the pharmacists and usual care
Study: NCT01551888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium/formoterol 400/12μg
Description: Aclidinium/formoterol 400/12μg fixed dose combination (FDC), one inhalation twice daily (morning and evening) for 4 days, then one inhalation (morning) on Day 5 via the Almirall inhaler
Study: NCT02269384

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Memory of Prior Significant Injury
Description: Subjects will visual prior significant injury or a predetermined lower extremity region in control subjects.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Memory of Prior Significant Injury
Description: Subjects will visual prior significant injury or a predetermined lower extremity region in control subjects.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mental Challenge Test
Description: Subjects will count backwards from 100 by specified amounts as rapidly as possible

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Mental Challenge Test
Description: Subjects will count backwards from 100 by specified amounts as rapidly as possible
Study: NCT03027193

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx2 HAV
Description: The ChAdOx2 HAV vaccine consists of the replication-deficient simian adenovirus vector ChAdOx2, containing the Mycobacterium avium subspecies paratuberculosis (MAP) antigens

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx2 HAV
Description: The ChAdOx2 HAV vaccine consists of the replication-deficient simian adenovirus vector ChAdOx2, containing the Mycobacterium avium subspecies paratuberculosis (MAP) antigens

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx2 HAV
Description: The ChAdOx2 HAV vaccine consists of the replication-deficient simian adenovirus vector ChAdOx2, containing the Mycobacterium avium subspecies paratuberculosis (MAP) antigens

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx2 HAV
Description: The ChAdOx2 HAV vaccine consists of the replication-deficient simian adenovirus vector ChAdOx2, containing the Mycobacterium avium subspecies paratuberculosis (MAP) antigens

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA HAV
Description: The MVA HAV vaccine consists of the replication deficient modified vaccinia virus Ankara (MVA) containing the Mycobacterium avium subspecies paratuberculosis (MAP) antigens.
Study: NCT01551888

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol
Description: Formoterol 12 μg one inhalation twice daily (morning and evening) for 4 days, then one inhalation (morning) on Day 5 via the Foradil® Aerolizer®
Study: NCT04360044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC ~5%
Description: 4 puffs of vaporized flower containing THC \~5%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD ~12%
Description: 4 puffs of vaporized flower containing CBD \~12%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC ~5% and CBD ~12%
Description: 4 puffs of vaporized flower containing THC \~5% and CBD \~12%

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham Cannabis
Description: 4 puffs of vaporized flower from which the THC and CBD have been extracted
Study: NCT03321162

Intervention type: DIAGNOSTIC_TEST
Intervention: scan protocol
Description: Scanning strategy is based on multiple scans. Essentially one CT scan of the patient (usually with a scan appliance). Another CT scan of the model or scan appliance may be required (double scan technique). Such a second CT scan can be replaced by optical scanning of the model and scan appliance (triple scan technique).
Study: NCT03525158

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Brief cognitive intervention
Description: A one-session intervention with a researcher including a simple cognitive task (a memory cue, 10 minutes time gap and ca. 20 minutes of Tetris game play) with instructions to engage in the task self-guided in the subsequent week.
Study: NCT01062737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASU
Study: NCT02641197

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AngioDefender
Description: Repeatability will be assessed by repeat AngioDefender (AD) testing of the same subject 1 hour apart, using the same AD device and operator.~Reproducibility will be assessed by comparing FMD scores obtained for the same subject, but using different AD devices and operators.
Study: NCT02788682

Intervention type: GENETIC
Intervention: WT+ Diplotype
Description: 3 or 4 vitamin D binding protein major alleles
Study: NCT03127644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Zirconium Cyclosilicate (ZS) 5g
Description: Suspension administered 5g orally three times daily for 48 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Zirconium Cyclosilicate (ZS) 10g
Description: Suspension administered 10g orally three times daily for 48 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo suspension administered orally placebo three times daily for 48 hours.
Study: NCT01058460

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HPV-cytology co-testing
Description: Subjects will receive HPV testing and conventional cytology testing at baseline. Follow up management will be based on both results.
Study: NCT03576183

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VLA1701
Description: VLA1701 is an investigational oral vaccine against LT-ETEC (Labile Toxin-Enterotoxigenic E coli)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: buffer component of VLA1701

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Challenge Strain
Description: LSN03-016011/A

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Challenge Strain
Description: LSN03-016011/A
Study: NCT03891186

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metacognitive Training in Schizophrenia (MCT)
Description: MCT is a group program with eight modules referring to common cognitive and biases in solving problems in schizophrenia. The following topics of MCT are: attribution blaming and taking credit (module 1), jumping to conclusions (modules 2 and 7), changing beliefs (module 3), deficits in theory of mind and social cognition (modules 4 and 6), overconfidence in (memory) errors (module 5) and depression and low self-esteem (module 8). Each session lasts 45 to 60 minutes and follows a protocol defined in the manual Metacognitive Training for Psychosis (MCT) that is currently available in 35 languages (available in www.uke.de/mkt).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual (TAU)
Description: In both groups will be maintained the TAU.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment As Usual (TAU)
Description: In both groups will be maintained the TAU.
Study: NCT02317718

Intervention type: OTHER
Intervention: monitor reproductive outcome